SPONSOR
Oncotherapeutics
Total Trials
2
Recruiting
2
Phases
Phase 2, EARLY_Phase 1
Oncotherapeutics is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Multiple Myeloma.
The trial portfolio spans Phase 2, EARLY_Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Oncotherapeutics
How many clinical trials has Oncotherapeutics sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Oncotherapeutics, of which 2 are actively recruiting participants. These trials cover conditions including Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Multiple Myeloma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Oncotherapeutics research focus on?
Oncotherapeutics clinical trials span Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Multiple Myeloma. The research pipeline includes Phase 2, EARLY_Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Oncotherapeutics clinical trial?
To participate in a Oncotherapeutics trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Oncotherapeutics trials with current recruitment status updated daily.
Clinical Trials by Oncotherapeutics
NCT06115135 Phase 2
Recruiting
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Multiple Myeloma in Relapse
NCT06209606 EARLY_Phase 1
Recruiting
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
Multiple Myeloma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology